Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Prostate Cancer – Current Treatment – Current Treatment: Physician Insights – Prostate Cancer (US)

Login to access report north_east
Contact sales account_box

Hormonal therapy is the cornerstone of drug treatment for prostate cancer in all patient populations. Abiraterone and Xtandi (Pfizer / Astellas Pharma) dominate the metastatic castrate-resistant prostate cancer (mCRPC) market and account for sizable market shares in the metastatic hormone-sensitive prostate cancer (mHSPC) setting. They compete with other next-generation hormonal therapies like Erleada (Janssen) and Nubeqa (Bayer HealthCare), two brands initially approved for nonmetastatic castrate-resistant prostate cancer (nmCRPC). The PSMA-targeted radioligand therapy Pluvicto (Novartis), which the FDA approved in March 2022, is having an impact on the treatment of mCRPC. The PARP inhibitors Lynparza (AstraZeneca) and Rubraca (Clovis Oncology) offer other biomarker-driven options for mCRPC treatment, and Xofigo (Bayer HealthCare) and Jevtana (Sanofi) are other nonhormonal treatment options for mCRPC, particularly in later lines.

Questions Answered

  • What are the drug-treatment rates across clinically and commercially relevant prostate cancer patient populations?
  • What is the uptake of the PSMA radioligand therapy Pluvicto in mCRPC to date?
  • What are the patient shares of key therapies in commercially relevant prostate cancer patient populations?
  • What are the main drivers of and obstacles to the uptake of current therapies in select hormone-sensitive and castrate-resistant patient segments?

Product Description

Current Treatment: Physician Insights provides physician insights ontreatment dynamics, prescribing behavior, and drivers of brand useso that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets covered: United States

Primary research: Survey of 100 medical oncologists and urologists (50 of each specialty) in the United States fielded in May 2023.

Key drugs covered: Abiraterone, Xtandi, Erleada, Nubeqa, Orgovyx, Pluvicto, Provenge, Xofigo, Jevtana, Lynparza, Rubraca, others

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
north_east
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
north_east
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
north_east
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
north_east
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east